(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...

A total of 545 subjects with episodic or chronic migraine, who are aged 18 and above, were included in the trial.

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

AbbVie Golden Ticket Comes to a ClosePress release2025-06-18 11:48AbbVie Golden Ticket ceremony at SmiLe Venture Hub.Lund, Sweden – The one-year AbbVie Golden Ticket program has officially concluded – ...

This was the stock's third consecutive day of losses.